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Abstract
Long-term hematopoietic stem cells (LT-HSC) and short-term hematopoietic stem cells (ST-HSC) have been characterized as
having markedly different in vivo repopulation, but similar in vitro growth in liquid culture. These differences could be due
to differences in marrow homing. We evaluated this by comparing results when purified ST-HSC and LT-HSC were
administered to irradiated mice by three different routes: intravenous, intraperitoneal, and directly into the femur. Purified
stem cells derived from B6.SJL mice were competed with marrow cells from C57BL/6J mice into lethally irradiated C57BL/6J
mice. Serial transplants into secondary recipients were also carried out. We found no advantage for ST-HSC engraftment
when the cells were administered intraperitoneally or directly into femur. However, to our surprise, we found that the
purified ST-HSC were not short-term in nature but rather gave long-term multilineage engraftment out to 387 days, albeit at
a lower level than the LT-HSC. The ST-HSC also gave secondary engraftment. These observations challenge current models
of the stem cell hierarchy and suggest that stem cells are in a continuum of change.
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Introduction
Elegant work, utilizing fluorescently labeled monoclonal
antibodies and fluorescence-activated cell sorting (FACS), has
progressively characterized the multilineage repopulation poten-
tial of different marrow cell populations. This work has formed
the basis for a detailed marrow stem/progenitor cell hierarchy
[1–23] in which the most primitive stem cells differentiate into
progressively more mature marrow cells with gains of specific
function and loss of proliferative, renewal, and total differenti-
ation potential. In this generally accepted model, the most
primitive cell is the long-term hematopoietic stem cell separated
on the basis of lineage negative status (Lin
2) and expression of
the surface epitopes c-kit and Sca-1 with either intermediate
Thy-1.1 expression or absence of Flk-2 [7]. This cell has long-
term repopulation and secondary repopulation potential in
lethally irradiated mice. Differentiation of the LT-HSC into
ST-HSC, a cell with a repopulation potential not exceeding 8-12
weeks, is then characterized by the gain of Flk-2 expression. Loss
of Thy-1.1 expression with full expression of Flk-2 characterizes
the next differentiation step to the multipotent progenitor (MPP).
Further differentiation and subdivision of these cells is then
characterized by additional selective epitope expression. LT-
HSC and ST-HSC subsetted by cycle status into stem cells
capable of long-term and short-term engraftment showed
equivalent proliferative potential in in vitro liquid culture
stimulated by cytokines [21]. The investigators speculated that
the difference between these cells might be based on differences
in marrow homing capacity. Accordingly, we initiated studies on
whether the route of administration of the marrow, intravenous,
intraperitoneally, or intrafemoral would affect the engraftment
outcomes of Lin
2c-kit
+Sca-1
+Flk-2
2 (LT-HSC) or Lin
2c-
kit
+Sca-1
+Flk-2
+ (ST-HSC/MPP) marrow cells. We found that
administering ST-HSC/MPP by intrafemoral or intraperitoneal
routes did not enhance their engraftment potential, but also
observed that the Lin
2c-kit
+Sca-1
+Flk-2
+ (ST-HSC/MPP) mar-
row cells gave rise to long-term stable engraftment. This work is
presented below.
Results
Marrow from B6.SJL donor mice was harvested, lineage
depleted, and stained with antibodies to c-kit, Sca-1, and Flk-2
as outlined in Methods (Figure 1). Cells were selected for c-kit
+,
Sca-1
+, and either Flk-2 negative or Flk-2 positive cells. The
former are the LT-HSC and the latter the ST-HSC/MPP. In
these studies, there was no selection for Thy-1.1 and, thus, the ST-
HSC population will also include multipotent progenitors (MPP).
Both these classes of stem cells are short term repopulators and are
designated here as ST-HSC/MPP. The isolated LT-HSC or ST-
HSC/MPP were then competed against C57BL/6J marrow into
lethally irradiated C57BL/6J host mice. Engraftment and lineage
analysis was determined by staining peripheral blood with
CD45.1, CD45.2, myeloid markers GR-1, and CD11b or
lymphoid markers B220 and CD3 as outlined in the Methods
section.
PLoS ONE | www.plosone.org 1 February 2012 | Volume 7 | Issue 2 | e31300Figure 2 plots several visualizations for chimerism from
Experiment 1. Individual mice, (Tile A) in both LT-HSC and
ST-HSC, exhibit bimodality over most time points with several
mice exhibiting higher chimerism while others show low. While
individual mice were not tracked, it is likely this results from
engraftment ‘‘taking’’ in some, but not others. This includes 3 mice
injected with ST-HSC that exhibited exceptional chimerism, and
3 mice injected with LT-HSC that showed poor or declining
chimerism. Consider these observations while examining Tile B.
In particular, note that the means for both groups of mice are
located in areas where virtually no individual mice observations
were located. Indeed, even the area covered when considering
standard error of the mean spans values that correspond to few, if
any, individual mice values over most time points. It can be argued
that the central tendency of the LT-HSC is underestimated and
that of the ST-HSC is overestimated, while variability was
underestimated for both. These observations demonstrate the
inappropriateness of single means and estimates of their variability
for describing bimodally distributed data. Two alternatives are
presented in Tiles C and D. Tile C indicates central tendency
using the median and variability based on the inter-quartile range,
which more appropriately spans the bimodal data. These compare
much more favorably to the individual observations and most
closely correspond to the distribution-free statistics used to
compare groups. Tile D dichotomizes mice into successful
engraftment vs. failed engraftment by employing a relatively
arbitrary, but conservative threshold of 10% chimerism, plotting
this proportion for each time point along with its binomial 95%
confidence interval. However, with such small sample sizes, this
option was considered overly conservative for analysis. Similar 4-
tiled figures are presented for each injection method for all
experiments. However, Figure 2 most clearly demonstrates the
issue of bimodality in the data, likely because its overall levels of
chimerism were higher than in other experiments.
Based on the distribution-free Wilcoxon rank-sum statistic (with
Holm adjustment for multiple comparisons), LT-HSC had
Figure 1. Sorting Scheme. Fluorescence-activated cell sorting of lineage negative (FITC
2) leukocytes to isolate long term- and short term-
hematopoietic stem cell groups. A) Forward and side scatter plot isolates cells. B) Forward scatter and PI plot captures living cells (PI
2). C) Forward
scatter and FITC plot removes remaining lineage
+ cells (FITC
+) and retains lineage
2 cells (FITC
2). D) Sca-1 (Alexa Fluor 405
+) and c-kit (APC
+) positive
cells are isolated. E) Forward scatter and Flk-2 plot separates long term cells (Flk-2
2 PE
2) from short term cells (Flk-2
+ PE
+). Stem cells in the LT-HSC
(Flk-2
2) (F1, F2) and ST-HSC (Flk-2
+) (G1, G2) groups were resorted to ensure that contaminating cells are not present in either population.
doi:10.1371/journal.pone.0031300.g001
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PLoS ONE | www.plosone.org 2 February 2012 | Volume 7 | Issue 2 | e31300significantly higher chimerism at 35 (adj.p,0.001) and 52
(adj.p=0.011) days post transplant in the primary recipients
compared to later time points (adj.p$0.05 for all). When whole
bone marrow harvested from the primary recipients was pooled
and subsequently transplanted into the secondary recipients, LT-
HSC had better chimerism than ST-HSC/MPP at Day 33
(adj.p=0.006), but not at Day 56 (adj.p=0.842). Interestingly,
when whole bone marrow was harvested from secondary
recipients at Day 84, ST-HSC/MPP chimerism was significantly
higher than that of LT-HSC (adj.p=0.020).
Engraftment was very low in mice receiving intraperitoneal
injections. These levels were so low as to defy statistical analyses.
Figure 3 is presented to demonstrate the low levels and for the sake
of completeness and consistency.
Figures 4 and 5 plot the 4-tiled figures for Experiment 2,
intravenous and intrafemoral injections, respectively. Statistical
analyses made comparisons between the 4 groups defined by cell
type (LT-HSC vs. ST-HSC/MPP) and injection method. There
were no statistically significant differences between groups at any
time point in primary recipients (adj.p$0.05 for all). Again, the
Figure 2. Experiment 1: intravenous injection. Chimerism (%CD45.1) (ordinate) plotted as a function of Days Post Transplant (abscissa), type of
cells injected (N&: LT-HSC, #%: ST-HSC), and source (N#: whole blood, &%: whole bone marrow) for several different methods of summary: A)
raw individual mouse percent CD45 cells that were CD45.1, B) mean 6 standard error of the mean, C) median with inter-quartile range, and D)
percent of mice with greater than 10% of CD45 cells being CD45.1. For each tile, the data from the primary transplant is plotted on the left and
secondary transplant on the right, separated by a vertical line at zero for the secondary transplant.
doi:10.1371/journal.pone.0031300.g002
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data. In the secondary recipients, however, LT-HSC injected
intravenously had higher chimerism than any other group at 33
days (adj.p,0.05 for all), and ST-HSC injected intravenously had
higher chimerism than the cell types injected intrafemorally
(adj.p,0.05 for both). At Day 68, LT-HSC and ST-HSC/MPP
did not differ significantly for either injection method (adj.p$0.05
for both). LT-HSC injected intravenously had higher chimerism
than LT-HSC injected intrafemorally (adj.p=0.028). In contrast,
ST-HSC/MPP injected intravenously had significantly higher
chimerism than either LT-HSC or ST-HSC/MPP injected
intrafemorally (adj.p,0.05 for both). The failure of LT-HSC
intravenously injected to reach statistical significance as com-
pared to ST-HSC/MPP injected intrafemorally, despite having a
higher median than ST-HSC/MPP injected intravenously,
reflected the wider variation in chimerism for LT-HSC than
ST-HSC/MPP, as suggested by the wider inter-quartile range.
This comparison was actually statistically significant prior to
adjustment for multiple comparisons with the Holm Test
(unadjusted p=0.0133).
Figure 3. Experiment 1: intraperitoneal injection. Chimerism (%CD45.1) (ordinate) plotted as a function of Days Post Transplant (abscissa), type
of cells injected (N&: LT-HSC, #%: ST-HSC), and source (N#: whole blood, &%: whole bone marrow) for several different methods of summary: A)
raw individual mouse percent CD45 cells that were CD45.1, B) mean 6 standard error of the mean, C) median with inter-quartile range, and D)
percent of mice with greater than 10% of CD45 cells being CD45.1. For each tile, the data from the primary transplant is plotted on the left and
secondary transplant on the right, separated by a vertical line at zero for the secondary transplant.
doi:10.1371/journal.pone.0031300.g003
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to further purify our marrow cells, in this third experiment we
performed a ‘‘double sort’’.
Figures 6 and 7 plot the 4-tiled figures for Experiment 3,
intravenous and intrafemoral injections, respectively. In contrast
to Experiment 2, there were statistically significant differences
between groups at all points in time for both primary and
secondary recipients. These were consistent and represented the
differences between LT-HSC injected intravenously and ST-
HSC/MPP injected via either method in primary recipients. All
such comparisons were statistically significant (adj.p,0.05)
excepting the comparisons with ST-HSC/MPP injected intrave-
nously at Days 173 and 201 (adj.p=0.057 and adj.p=0.068,
respectively), which were not statistically significant after adjust-
ment with the Holm Test (unadjusted p=0.002 and p=0.003,
respectively). No other comparisons were statistically significant
within primary recipients. The pattern of superiority in intrave-
nously injected LT-HSC continued and developed further in
secondary recipients. Here, LT-HSC intravenously injected had
higher chimerism at all three points in time (adj.p,0.05 for all),
Figure 4. Experiment 2: intravenous injection. Chimerism (%CD45.1) (ordinate) plotted as a function of Days Post Transplant (abscissa), type of
cells injected (N&: LT-HSC, #%: ST-HSC), and source (N#: whole blood, &%: whole bone marrow) for several different methods of summary: A)
raw individual mouse percent CD45 cells that were CD45.1, B) mean 6 standard error of the mean, C) median with inter-quartile range, and D)
percent of mice with greater than 10% of CD45 cells being CD45.1. For each tile, the data from the primary transplant is plotted on the left and
secondary transplant on the right, separated by a vertical line at zero for the secondary transplant.
doi:10.1371/journal.pone.0031300.g004
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between short-term intravenously and intrafemorally injected cells
at Day 98 (adj.p=0.0369).
In all three experiments, engraftment for LT-HSC and ST-
HSC/MPP was observed to be multilineage in nature as shown
in Figure 8 and described in Methods. For each experiment,
peripheral blood was analyzed for percent donor contribution to
myeloid lineages, represented by CD11b
+ and GR1
+ cells, and
lymphoid lineages, represented by B220
+ and CD3
+ cells, at
various time points. For Experiments 1 and 2, analyses were
done at 2, 4, 6, 8, and 12 months post-transplant. For
Experiment 3, analysis was done at 1, 2, 4, 6, and 8 months
following transplant. At all time points for all experiments, when
donor engraftment occurred, this engraftment was multilineage.
The donor contribution to myeloid and lymphoid lineage was
stable over time in both primary and secondary transplants and
similar to results seen with whole bone marrow analysis (data not
shown).
Figure 5. Experiment 2: intrafemoral injection. Chimerism (%CD45.1) (ordinate) plotted as a function of Days Post Transplant (abscissa), type of
cells injected (N&: LT-HSC, #%: ST-HSC), and source (N#: whole blood, &%: whole bone marrow) for several different methods of summary: A)
raw individual mouse percent CD45 cells that were CD45.1, B) mean 6 standard error of the mean, C) median with inter-quartile range, and D)
percent of mice with greater than 10% of CD45 cells being CD45.1. For each tile, the data from the primary transplant is plotted on the left and
secondary transplant on the right, separated by a vertical line at zero for the secondary transplant.
doi:10.1371/journal.pone.0031300.g005
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Our studies indicate that changes in the route of administration
of ST-HSC/MPP to intraperitoneal or intrafemoral routes, in
general, did not result in engraftment equivalent to that seen when
LT-HSC were administered intravenously, thus indicating that
differences between engraftment of these cell types was not due to
differences in homing efficiency. However, this point is essentially
moot since the ST-HSC/MPP cells showed prolonged multi-
lineage engraftment and secondary engraftment. This is in
contrast to previous reports of short-term engraftment of marrow
cells selected based on lineage negativity, and c-kit, Sca-1, and Flk-
2 positivity. The expression of Flk-2 has correlated with stem cell
differentiation and loss of self renewal capacity and generally
marks the transition from LT-HSC to ST-HSC/MPP, although
some cells with characteristics of LT-HSC may express low levels
of Flt3 [14]. Cells isolated, as described here in the standard
lineage, would be considered to be at the ST-HSC or MPP levels
and not have the capacity for long-term multilineage repopulation.
There have been a number of studies analyzing various
characteristics of ST-HSC/MPP but, in general, these studies
have not included confirmation of the in vivo engraftment
Figure 6. Experiment 3: intravenous injection. Chimerism (%CD45.1) (ordinate) plotted as a function of Days Post Transplant (abscissa), type of
cells injected (N&: LT-HSC, #%: ST-HSC), and source (N#: whole blood, &%: whole bone marrow) for several different methods of summary: A)
raw individual mouse percent CD45 cells that were CD45.1, B) mean 6 standard error of the mean, C) median with inter-quartile range, and D)
percent of mice with greater than 10% of CD45 cells being CD45.1. For each tile, the data from the primary transplant is plotted on the left and
secondary transplant on the right, separated by a vertical line at zero for the secondary transplant.
doi:10.1371/journal.pone.0031300.g006
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studied cells separated on this basis.
In separate studies, we have forwarded a non-hierarchical
model of stem/progenitor cell regulation based on observations of
a continuously and reversibly changing cell phenotype tied to cell
cycle status [23–36]. In this model, phenotype lability of stem cells
is assumed. We have documented reversible changes of stem cells
as to engraftment [1,24,25,27], differentiation [34], marrow
homing [30], adhesion protein and cytokine receptor expression
[28,29,31], and gene expression linked to cell cycle phase [1,23],
and our recent work has also indicated that the long-term
repopulating cell in the marrow is a cycling cell. (Unpublished
observations: Quesenberry PJ, Dooner MS, Goldberg LR, 2009.)
Earlier work on colony-forming unit-spleen (CFU-s) by Necas and
Znojil [37] indicated that this putative stem cell showed marked
quantitative changes and alterations in cell cycle status in different
experiments and between individual mice. These investigators
proposed that there might be bursts of cycle activity separate from
circadian changes. Lastly, we have previously documented marked
changes in 10 week engraftment at different circadian times, and
this also changed on a seasonal basis [38]. Thus, there are many
potential explanations for these results not matching those initially
Figure 7. Experiment 3: intrafemoral injection. Chimerism (%CD45.1) (ordinate) plotted as a function of Days Post Transplant (abscissa), type of
cells injected (N&: LT-HSC, #%: ST-HSC), and source (N#: whole blood, &%: whole bone marrow) for several different methods of summary: A)
raw individual mouse percent CD45 cells that were CD45.1, B) mean 6 standard error of the mean, C) median with inter-quartile range, and D)
percent of mice with greater than 10% of CD45 cells being CD45.1. For each tile, the data from the primary transplant is plotted on the left and
secondary transplant on the right, separated by a vertical line at zero for the secondary transplant.
doi:10.1371/journal.pone.0031300.g007
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which have not been considered in a number of previous
experiments.
Recent work has emphasized the importance of CD150, CD48,
or CD41 in stem cell separations, and these were not utilized in
our current set of experiments [39,40]. However, this is
appropriate, because these also were not utilized in the initial
experiments defining LT-HSC and ST-HSC/MPP. In addition,
the utilization of another surface marker to subset stem cells,
simply, is a further measure of the heterogeneity of the stem cell
population and does not provide a truer picture of the stem cell
[41]. As we have proposed earlier, stem cell purifications leave
behind most stem cells and this is not a random procedure [42].
Thus, it is questionable whether a marrow cell purified on the basis
of surface epitope selection is truly representative of marrow stem
cells in the whole organism. Our work on determining the cell
cycle status of purified and whole marrow cells indicates that quite
different cycle results are obtained with the cell cycle status of
purified as opposed to unseparated marrow stem cells. It is of
interest that there remains some controversy as to the ultimate
meaning of CD150 marking for stem cells: we feel that the
addition of this marker adds little to our understanding of
hematopoietic marrow stem cells. Finally, a very intriguing report
suggested that antibody binding to stem cells in these separations
might have very significant inhibitory effects on their engraftment
capacity [43]. These studies imply that antibody based purification
of stem cells is inherently flawed, however, a major question in
these studies is whether the antibody binding altered the stem cell
separation and, thus, these results at present are not definitive.
Follow-up studies can resolve this question. Finally, it is possible
that methodologic differences between studies could underlie the
different results. The standard LT-HSC/ST-HSC separations, as
described by the Weissman group, did not employ an initial
preparative density separation which was utilized in the current
study. Overall, it is fair to state that there are many unanswered
questions as to the meaning and validity of stem cell separations.
In summary, we did not find that homing differences explained
differences in engraftment capacity between marrow cells differing
in Flk-2 expression, and we have found that the classic ST-HSC/
MPP phenotype in our experiments does not match that initially
reported. More generally, we would expect to see a great deal of
stem cell phenotype variation depending upon cell cycle status,
circadian time, and other stochastic influences. We feel that the
previously defined hierarchical stem cell classes actually represent
a very fluid population, and that surface phenotype does not
accurately define stem cell populations. We propose that a major
challenge to the field is not to purify stem cells but rather to define
the whole stem cell population.
Materials and Methods
Mice
Six- to eight-week-old, congenic, male B6.SJL-Ptprc
aPepc
b/BoyJ
(B6.SJL) and male C57BL/6J mice were purchased from The
Jackson Laboratory (Bar Harbor, ME). Animals were housed for
at least one week prior to use in a conventional clean facility with
12 hour light-dark cycles and access to mouse chow and water ad
libitum in accordance with the National Research Council’s Guide
for the Care and Use of Laboratory Animals [44]. All procedures were
approved by the Rhode Island Hospital Institutional Animal Care
and Use Committee.
LT-HSC and ST-HSC/MPP Purification
B6.SJL mice, 10–12 weeks of age, anesthetized with isoflurane,
were killed by cervical dislocation. Bone marrow was harvested
from the iliac crests, femurs, tibiae, and spines by crushing in a
mortar with a pestle and 16phosphate buffered saline containing
5% heat-inactivated fetal calf serum and 1% penicillin-streptomy-
cin (PBS-HIFCS), as previously described [45]. The crushed
marrow was washed extensively with fresh PBS-HIFCS. The wash
volumes held in 50 ml conical tubes were filtered through 40 mm
nylon cell strainers to remove small bone particles and were pooled
for a cell count and centrifugation. The cell pellet was resuspended
in fresh PBS-HIFCS to a final concentration of 1610
7 cells per ml.
Each 30 ml of cell suspension was mixed with 10.1 ml of
Optiprep
TM (AXIS-SHIELD PoC AS, Oslo, Norway) density
gradient solution and 4 ml of sterile, distilled water in 50 ml
conical tubes. Each tube was overlaid with 5 ml PBS-HIFCS and
centrifuged at 10006 g for 30 minutes without acceleration or
braking. A low-density leukocyte cell fraction (,1.077 g/ml) was
isolated per manufacturer’s instructions. This fraction was washed
and then lineage depleted by incubation with rat IgG anti-mouse
monoclonal antibodies to B220, CD4, CD8a, CD11b, TER119
[0.1 mg/10
6 cells], CD3, CD5 [0.25 mg/10
6 cells], and GR1
[0.5 mg/10
6 cells] (BD Pharmingen, San Diego, CA except CD3
which is from SouthernBiotech, Birmingham, AL). The lineage
positive cells were removed with DynabeadsH, sheep anti-rat IgG-
conjugated super-paramagnetic polystyrene beads (4.5 mmi n
diameter) (DynalH Magnetic Bead System, Invitrogen, Carlsbad,
CA) per manufacturer’s instructions. Immunomagnetic bead-
rosetted cells were removed using a magnetic particle concentrator
(DynalH, MPC-6), and the unrosetted cells remaining in
Figure 8. Multilineage nature of engraftment: Summary graph of all primary transplant experiments showing that when
engraftment occurred, multiple cell types were seen. Therefore, points displayed represent percent of cells from donor. Serial transplants of
the primary whole bone marrow were also multilineage in nature when engraftment occurred (data not shown).
doi:10.1371/journal.pone.0031300.g008
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negative cells. They were transferred to a fresh tube and incubated
with: biotin-conjugated Sca-1, allophycocyanin (APC)-conjugated
c-kit, phycoerythrin (PE)-conjugated Flk-2 (BD Pharmingen, San
Diego, CA), and FITC-conjugated rat polyclonal IgG
(eBioscience, San Diego, CA) [0.25 mg/10
6 cells]. The cells were
washed with PBS-HIFCS and incubated with streptavidin-Alexa
Fluor 405 [0.5 mg/10
6 cells] (Invitrogen, Carlsbad, CA) for
15 minutes on ice. Following a final wash in PBS-HIFCS, the
cells were re-suspended to a concentration of 50610
6 cells/ml in a
1 mg/ml propidium iodide solution (PI) (Sigma, St. Louis, MO).
Fluorescence-Activated Cell Sorting (FACS)
LT-HSC were isolated by flow cytometry and defined as
follows: lineage negative (FITC negative), c-kit (APC) positive, Sca-
1 (Alexa Fluor 405) positive, and Flk-2 (PE) negative. ST-HSC/
MPP were defined as lineage negative (FITC negative), c-kit (APC)
positive, Sca-1 (Alexa Fluor 405) positive, and Flk-2 (PE) positive.
Dead cells were gated out based on high PI staining. Cell sorting
was performed using a BD Influx
TM cell sorter (BD Bioscience,
San Diego, CA) equipped with the following: a 100 mW 488 nm
sapphire, a 100 mW UV, a 405 nm violet, a 635 nm red, and a
561 nm green/yellow lasers. Propidium iodide was excited using
the UV laser and emission collected through a 670/30 nm filter.
The 488 nm laser was used to excite FITC, while PE was excited
by the 561 nm laser. Fluorescent emission was collected using
528/38 nm and 610/20 nm filters, respectively. Alexa Fluor 405
was excited using the 405 nm laser, and emission was collected
through a 460/50 nm filter. The 635 nm red laser was used to
excite APC, and the fluorescent emission was collected through a
670/30 nm filter.
The cell suspension was gently vortexed and kept at 4uC
throughout the sort. A gate was set around cells in the side scatter
versus forward scatter plot (Figure 1A). Dying or dead cells were
gated out based on high PI staining (Figure 1B). Any remaining
FITC-tagged lineage positive/low cells were then gated out
(Figure 1C). Sca-1/c-kit double positive cells were gated in
(Figure 1D). These cells were then sorted into separate tubes based
on Flk-2 staining (Figure 1E). In one experiment, the Flk-2
negative and the Flk-2 positive sorted cell populations were
resorted individually to confirm purity based on their Flk-2
staining (Figure 1 F1,F2 and G1,G2) respectively.
Irradiation and Stem Cell Transplantation
C57BL/6J recipient mice received 950 cGy irradiation
(GammacellH 40 Exactor,
137Cesium source irradiator) (Best
Theratronics Ltd., Ottawa, Ontario, Canada) in two fractions,
three hours apart, at a rate of 107 cGy per minute. Cells were
infused within three hours post irradiation. Each mouse received
either 200–500 LT-HSC (B6.SJL) combined with 300,000
C57BL/6J competitor whole marrow cells or 200–500 ST-
HSC/MPP (B6.SJL) combined with 300,000 C57BL/6J compet-
itor cells by one of three injection routes: intravenous (IV),
intraperitoneal (IP), or intrafemoral (IF). The IV and IP volumes
were 0.5 ml per animal, and the IF volume was 0.02 ml per
anesthetized animal. Prior to IF injection, mice were anesthetized
using ketamine (75 mg/kg) and medetomidine (1 mg/kg) intra-
peritoneally. Once anesthetized, the region from the inguen to the
knee was sterilized with 70% ethyl alcohol and 10% povidone
iodine (Betadine). With one hand, the knee was flexed to 90u,
effectively securing the leg to prevent motion while performing the
procedure. With the other hand, a 27-gauge U-100 needle
(Terumo Medical Corporation, Elkton, MD) was carefully inserted
into the joint surface of the distal femur above the patella, through
the patellar tendon, and then the stem cells were slowly injected
into the bone marrow cavity [46–48].
Serial Secondary Whole Bone Marrow Transplantation
At eight months or one year after cell infusion, the mice from
the primary transplant experiments were sacrificed and whole
bone marrow from femurs and tibiae was harvested. The marrow
from each group was pooled, and 6610
6 cells per mouse were
serially transplanted via tail vein injection to a new set of lethally
irradiated mice. Engraftment of B6.SJL cells was analyzed at
multiple time points after secondary transplant (vide infra).
Engraftment and Lineage Analysis
Peripheral blood from primary or secondarily engrafted mice
was obtained at varying times from the tail vein, utilizing EDTA as
an anticoagulant. Chimerism and the lineage of the repopulating
cells were determined by flow cytometric analysis. Whole blood
was split into two aliquots and labeled for 30 minutes with either,
CD45.1 FITC, CD45.2 PerCP-Cy5.5, B220 PE, and CD3 APC
antibodies (lymphoid lineage master mix) or CD45.1 FITC,
CD45.2 PerCP-Cy5.5, CD11b PE, and GR-1 APC antibodies
(myeloid lineage master mix) (BD Pharmingen, San Diego, CA) in
PBS pH 7.2 containing 0.5% FBS and 0.2% sodium azide (FACS
buffer). The samples were subsequently incubated with 16Pharm
Lyse
TM ammonium chloride-based lysing reagent (BD Pharmin-
gen, San Diego, CA) and washed with FACS buffer to remove red
blood cells. Samples were resuspended in FACS buffer and
analyzed on a BD LSR II
TM flow cytometer (BD Bioscience, San
Jose, CA). A plot of forward and side scatter was gated to eliminate
debris and a plot of forward scatter area and width to eliminate
doublets. A minimum of 10,000 events were collected. Appropri-
ate compensation controls were set to avoid spectral overlap. The
percentage of CD45.1 (donor) engrafted was determined by
dividing the number of CD45.1 positive events by the sum of
CD45.1 positive plus CD45.2 positive events and multiplying this
result by 100.
In order to determine the lineage of the transplanted
repopulating cells, all CD45.1 positive cells were analyzed for
expression of the lymphoid markers B220 and CD3 and for the
expression of the myeloid markers CD11b and GR-1. For
example, the percentage of B220 positive donor cells was
determined by dividing the number of CD45.1 positive, B220
positive cells by the sum of CD45.1 positive, B220 positive cells
and CD45.1 positive, B220 negative cells and multiplying this
value by 100.
Statistical Methods
The distribution of percent chimerism was not normal and
frequently bimodal, with a portion of the group exhibiting one
pattern (e.g., higher) than the rest of the group. This was
particularly apparent in the first experiment, where chimerism was
overall higher. The bimodal nature of the data made the use of
standard parametric statistics inappropriate (e.g., t-test or analysis
of variance). Therefore, distribution-free statistics based on rank-
sums were used. Unfortunately, there are currently no non-
parametric equivalents to the parametric statistics capable of
analyzing higher order designs, particularly not ones with repeated
measures (e.g., two-way analysis of variance or mixed models).
Therefore, independent rank-sum statistics were used to compare
groups at each time point, with p-values adjusted for alpha
inflation using the Holm test [49], as described in more detail
below.
There were only 2 groups of animals in Experiment 1 because
intraperitoneal injection data was not analyzed. The analysis of
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PLoS ONE | www.plosone.org 10 February 2012 | Volume 7 | Issue 2 | e31300this experiment used a single Exact Wilcoxon Rank-Sum test at
each time point. Experiments 2 and 3 included 4 groups of
animals. Here, the Kruskal-Wallis test was used as an omnibus test
for any differences between groups. If this was statistically
significant, then follow-up pair-wise comparisons were made
between the 4 groups using the Exact Wilcoxon Rank-Sum test.
The p-values of all comparisons within an experiment were
adjusted for Type I error inflation using the Holm test. The
relatively large number of comparisons makes this technique
somewhat conservative and, so, unadjusted p-values are noted
occasionally in addition to the adjusted p-values when results may
seem counterintuitive or otherwise inconsistent, with possible Type
II error implicated.
The occurrence of bimodality presented a difficult analytic
problem, which was mirrored in the choice as to how to visualize
the results. Presentation of the mean of bimodal data is particularly
problematic. Therefore, a 4-tiled figure was created for each
experiment and injection protocol in which several methods for
visualizing are contrasted, including the conventional mean-based
technique. The four tiles present visualizations: A) the raw
individual points for each mouse, B) the mean 6 standard error
of the mean, C) the median with inter-quartile range, and D) the
percent of mice exceeding 10% chimerism with 95% confidence
intervals. Each is plotted as a function of days post transplant, cell
type transplanted (LT-HSC vs. ST-HSC), and source (whole blood
vs. whole bone marrow). The third tile, labeled ‘‘C’’, was chosen as
the closest representation to the statistical analyses conducted.
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